Cambridge Cognition Holdings PLC Launch of web-based testing for virtual research
07 March 2017 - 6:02PM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
07 March 2017
07 March 2017
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Cambridge Cognition launches web-based testing for virtual
research
The global neuroscience digital health company Cambridge
Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops
and markets software products to improve brain health, today
announces the launch of a new web-based testing product for
conducting academic and clinical research studies online.
Disorders affecting the brain are now the leading cause of
disability and ill health worldwide. More than 1,000 disorders of
the brain and central nervous system (CNS) result in huge costs,
more hospitalisations and loss of productivity than any other
disease group, including heart disease and cancer(1) .
Advances in research will improve this outlook but
administrative costs, inadequate research tools and limited access
to patient populations can slow progress.
To support neuroscience research, CANTAB Connect, the worlds
most validated cognitive assessment software now enables
researchers to assess participants on a global scale, in a quick
and cost-effective manner.
Cambridge Cognition's CANTAB(R) technology has been used to
measure cognitive function in leading academic and industry
research for over 30 years. The Company now markets a range of
digital health products on mobile and wearable devices to help
recruit participants into clinical trials, validate treatment
efficacy and monitor brain health in daily life.
Web-based testing is the latest innovation, empowering
researchers to run near-patient testing of participants remotely.
The innovation will allow studies to gather digital cognitive
biomarkers at frequent time-points for more accurate and rapid data
to aid earlier decision-making and conduct large-scale research
projects virtually, reducing the overall running costs of studies
using proven neuropsychological assessments.
Dr Steven Powell, Chief Executive Officer, Cambridge Cognition,
commented: "The increasing prevalence of neurological and
psychiatric disorders including depression, Parkinson's and
Alzheimer's disease has resulted in a growing need for innovative
neuroscience digital health tools. Web-based testing using CANTAB
Connect is a key part of our strategy to provide scientifically
proven products to assist researchers and healthcare professionals
in improving brain health worldwide."
For information about web-based cognitive testing:
Visit: www.cantab.com/connect
Watch: https://www.youtube.com/watch?v=JbkX98xkkb8
(1) Society for Neuroscience.
https://www.sfn.org/about/about-neuroscience [last accessed 20
February 2017]
Notes to editors
About Cambridge Cognition Holdings PLC
Cambridge Cognition is a neuroscience digital health company
specialising in the precise measurement of clinical outcomes in
neurological disorders. The Company develops and markets validated
in-patient assessment software products to improve understanding,
diagnosis and treatment in global brain health.
www.cambridgecognition.com
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Marketing press@camcog.com
and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
Geoff Nash / Simon Hicks 0500
Alice Lane (Corporate Finance)
(Corporate Broking)
Dowgate Capital Stockbrokers Limited Tel: 01293 517
(Joint Broker) 744
David Poutney / James Serjeant
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGGFNVKGNZM
(END) Dow Jones Newswires
March 07, 2017 02:02 ET (07:02 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024